Impact of Gilenya on Cognitive Function and Thalamic Volume Measured by 7 Tesla MRI in Multiple Sclerosis
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 13 Nov 2018
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- 01 Nov 2018 Planned End Date changed from 31 Dec 2018 to 1 Dec 2019.
- 01 Nov 2018 Planned primary completion date changed from 31 Dec 2018 to 1 Oct 2019.
- 01 Nov 2018 Status changed from recruiting to active, no longer recruiting.